Immatics NV is set to report second-quarter earnings on Wednesday, with analysts projecting a narrower loss and significant revenue growth compared to the prior year. The clinical-stage cancer immunotherapy developer is expected to post a loss of €0.42 per share for the quarter ended June 30, roughly flat sequentially but representing a 27% improvement from the year-ago period.
Revenue is forecast at €10.3 million, a 35% increase from the €7.6 million reported in the first quarter and a 116% jump from the same period last year. Immatics previously missed first-quarter expectations by 28%, reporting €7.6 million against forecasts of €10.6 million. The company’s market valuation stands at $1.26 billion, with shares trading around $9.25, near the midpoint of its 52-week range between $5.05 and $12.41.
Analyst coverage remains uniformly bullish, with all eight firms maintaining buy ratings. The consensus price target is $17.87, implying a 93% upside from current levels. Over the past two months, EPS estimates have edged 1.6% higher and revenue estimates have risen 1.8%.
Immatics has highlighted progress in its pipeline, presenting Phase 1 data for its PRAME and MAGEA4/8 TCR programs at the American Society of Clinical Oncology meeting in June. The company’s lead candidate, anzu-cel, is advancing through a Phase 3 trial in previously treated advanced melanoma, with enrollment expected to complete this year. Additional trials, including the SUPRAME melanoma study, are also underway.
